Mumbai, 17 November 2025

 

The Department of Atomic Energy (DAE), in collaboration with Cologenesis Pvt. Ltd., today announced the commercial launch of ColoNoX, an advanced nitric oxide-releasing wound dressing developed to address the growing need for effective treatment of diabetic foot ulcers (DFU) in India.

The technology, developed by the Bhabha Atomic Research Centre (BARC) (Indian Patent No. 300809, September 2018), was initially incubated with Cologenesis Healthcare Pvt. Ltd., which subsequently conducted Phase II and III clinical trials. Following successful incubation, an exclusive licence for commercialisation was granted to Cologenesis Pvt. Ltd. under BARC’s Technology Transfer Programme. This marks a significant advancement in wound-care technology and is the first of its kind in India. The company has also secured the DCGI (CDSCO) licence (Permission No: MFG/MD/2024/000647) for manufacturing and commercialisation of the NOx-releasing wound dressing.

Speaking at the event, Dr. Ajit Kumar Mohanty, Secretary, DAE and Chairman, AEC, stated that the launch of ColoNoX represents a major step forward in providing effective and affordable DFU treatment options in India. He said, “This initiative reflects our commitment to the motto ‘राष्ट्र की सेवा में परमाणु’ (Atoms in the service of the nation), where we aim to harness scientific innovation for societal benefit.” He added that the initiative is also aligned with the Government of India’s vision of ‘Make in India’ and ‘Make for the World’.

Shri Vivek Bhasin, Director, BARC, appreciated the collaborative efforts of BARC scientists and Cologenesis Healthcare Pvt. Ltd. in successfully translating this innovation from laboratory research to commercial deployment. He noted that ColoNoX is expected to significantly enhance the management of diabetic foot ulcers and help minimise the risk of foot damage.

India faces a considerable healthcare burden due to the high prevalence of diabetes, with a large number of patients at risk of developing diabetic foot ulcers requiring specialised treatment. ColoNoX provides an innovative approach to DFU management by delivering therapeutically optimised nitric oxide (NOx) directly to the wound. The dressing promotes healing through the antimicrobial and regenerative benefits of nitric oxide, combined with the established wound-healing properties of collagen. The collagen hydrogel component also aids in reducing pain and absorbing wound exudates, thereby creating an optimal environment for healing, according to Mr. Krishna Kumar, Director, Cologenesis Healthcare Pvt. Ltd., Salem, Tamil Nadu, who was present during the launch.

 

* * *

PIB Mumbai | Edgar Coelho/Darshana Rane

 

Follow us on social media:@PIBMumbai    /PIBMumbai    /pibmumbai  pibmumbai[at]gmail[dot]com  /PIBMumbai    /pibmumbai

(Release ID: 2190910) Visitor Counter : 650